HETANG Venture Capital
荷塘创投基金
HETANG Venture Capital (荷塘创投) appears in elsewhere's corpus only through its deal activity, not a dedicated profile — so what's on record is a pattern of participation rather than a full biography. Across 2023–2025, it shows up repeatedly as a healthcare and biotech investor: it led the Series A of CAS-Ruiyi (中科睿医), a neurological-disease diagnostics company, per a BlueRun Ventures announcement , and later participated in its Series A+ ; it co-invested in Sainuo Bio's several-hundred-million-yuan Series C+ led by Source Code Capital ; it joined Inming Biotech's 700-million-yuan Series A ; and most recently, in November 2025, it followed Qiming Venture Partners into Ronghe Medical's near-100-million-yuan Series B in respiratory interventional therapy, where the founder named Qiming and HETANG together as "widely respected top-tier investment institutions" .
Taken together, the corpus paints it as an active life-sciences VC — spanning diagnostics, sequencing, and interventional devices — but elsewhere has no article covering the fund itself (its founding, team, or fund size), so that part of the picture isn't available here.
AI-generated — may contain errors, please verify.
Coverage
Raybeam Medical Raises Tens of Millions in Angel Round Led by Dalton Venture to Advance Laparoscopic Intraoperative Radiation Therapy Robot
Recently, **Raysure Medical (hereinafter referred to as "Raysure"), an innovative company developing intraoperative radiotherapy robots for endoscopic surgery, announced the completion of a multimillion-yuan angel funding round**. The round was led by Dalton Venture, with participation from Shuimu Tsinghua Alumni Fund, Fortera Capital, and HETANG Venture Capital. The proceeds will be used primarily for animal and clinical trials, product technology iteration, core team expansion, and technology platform development.
Qiming Venture Partners Weekly | Portfolio Company Updates and Funding News Vol. 41, 2025
Staying with you through milestone moments for Qiming Venture Partners portfolio companies
Qiming Venture Partners Leads Nearly 100 Million Yuan Series B Round in Ronghe Medical, Ushering in New Era for Respiratory Interventional Therapy
Going forward, Ronghe Medical will continue to focus on the frontier of life sciences, deepening the expansion and integration of its core technology matrix, and dedicating itself to developing original medical device solutions with significant clinical value.
CereMediTech Successfully Completes Series A+ Funding Round | BlueRun Ventures
Building the "New Infrastructure" for Diagnosing and Treating Neurological Disorders
Autumn's Prime: Six FreeS Fund Early-Stage Portfolio Companies Raise Nearly 1 Billion RMB | FreeS Family Funding News Vol.15
Looking forward to working alongside more outstanding founders.
Source Code Capital | "Sainuo Biology" Completes Hundreds of Millions of RMB in Series C+ Funding, Led by Source Code Capital
With this round of capital, Sainuo Bio will stay true to its founding mission, leverage its team's proprietary R&D strengths, actively refine its product portfolio, and vigorously advance its commercialization efforts.
CereMediTech Completes Tens of Millions of Yuan in Series A Funding to Advance Intelligent Diagnosis and Treatment Infrastructure for Neurological Diseases | BlueRun Ventures
Intelligent Technology Solutions for Full-Spectrum Neurological Diseases
